Performance of a Revised Cardiac Troponin Method That Minimizes Interferences from Heterophilic Antibodies
Authors:
Open Access
- 1 July 2002
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 48 (7) , 1028-1034
Abstract
Background: Recent guidelines for use of cardiac troponin to detect cardiac damage and for cardiovascular risk stratification have made increasingly sensitive troponin assays important. Troponin assays continue to be plagued by interferences caused by heterophilic antibodies (HAs). We evaluated the performance of a revised cardiac troponin I (cTnI) assay designed to have increased analytical sensitivity and to minimize the effect of HAs. Methods: The revised Dade Behring Dimension® cTnI assay was evaluated according to NCCLS EP5-A at five institutions. Plasma samples from 14 309 patients were assayed by the original Dimension cTnI assay. To identify samples that may have interfering HAs, samples with values >1.4 μg/L were reanalyzed on the Dade Behring Stratus® CS cTnI assay. Samples with possible interfering antibodies were also analyzed before and after selective absorbance studies on the revised Dade Behring Dimension cTnI assay. Results: The limit of quantification in the revised method was 0.1 μg/L with imprecision (CV) of 11–17% at 0.1 μg/L. Values correlated well with the Stratus CS cTnI method: revised = 1.06(original) + 0.01; r = 0.98, Sy|x = 0.25 μg/L). Falsely increased results consistent with myocardial infarction by the original Dimension cTnI assay and presumably attributable to HAs were identified in 0.17% of all patients with samples submitted for cTnI analysis. The revised Dimension cTnI assay eliminated the interference in 17 of 25 samples identified and greatly decreased the interference in the other 8. Conclusions: The revised Dimension cTnI method greatly minimizes the effect of interfering HAs. It also exhibits analytical performance characteristics consistent with recent guidelines for use of this assay to detect cardiac damage.Keywords
This publication has 26 references indexed in Scilit:
- Troponin measurements in ischemic heart disease: more than just a black and white picture∗∗Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.JACC, 2001
- Cardiac Troponins in Suspected Acute Coronary SyndromeCardiology, 2001
- ACC/AHA guidelines for the management of patients with unstable angina and non–st-segment elevation myocardial infarctionJACC, 2000
- Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarctionJACC, 2000
- Lower Cardiac Troponin T and I Results in Heparin-Plasma Than in SerumClinical Chemistry, 2000
- Troponin T and I Assays Show Decreased Concentrations in Heparin Plasma Compared with Serum: Lower Recoveries in Early than in Late Phases of Myocardial InjuryClinical Chemistry, 2000
- Analytical and Clinical Evaluation of Troponin I Determination on Dimension RXL-HMClinical Chemistry and Laboratory Medicine (CCLM), 2000
- Falsely Elevated Digoxin Level of 45.9 ng/mL Due to Interference from Human Antimouse AntibodyJournal of Toxicology: Clinical Toxicology, 2000
- When Do Microbes Stimulate Rheumatoid Factor?Journal of Experimental Medicine, 1997
- THE INCIDENCE OF ANTIBODY FORMATION TO OKT3 CONSEQUENT TO ITS USE IN ORGAN TRANSPLANTATIONTransplantation, 1995